BeiGene Appoints Chan Lee as General Counsel
July 13 2022 - 9:00AM
Business Wire
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology biotechnology company focused on developing and
commercializing innovative and affordable medicines to improve
treatment outcomes and access for patients worldwide, today
announced the appointment of Chan Lee as General Counsel, effective
July 18, 2022.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220713005323/en/
Chan Lee, General Counsel, BeiGene
(Photo: Business Wire)
Mr. Lee joins BeiGene from Sanofi and will bring his significant
expertise leading legal functions in the biopharma industry to
overseeing legal, compliance, intellectual property and related
matters. Mr. Lee succeeds Scott Samuels, who built BeiGene’s global
legal and compliance team and served as an important part of the
company’s evolution to a global commercial organization.
“Chan Lee is a proven leader in the biopharma industry and will
be a valued partner to me and to our executive team. His expertise
will strengthen BeiGene as we continue to expand globally and will
be instrumental in advancing our business priorities,” said
Co-Founder, Chairman, and CEO John V. Oyler. “I would also like to
thank Scott Samuels for his significant contributions to BeiGene’s
growth over the past several years, including establishing a
strong, worldwide legal function.”
Mr. Lee most recently served as North America General Counsel
and Head of Legal for Specialty Care Global Business Unit at
Sanofi, responsible for the legal oversight of Sanofi’s operations
in the U.S. and Canada and Specialty Care business globally. Prior
to Sanofi, he held roles of increasing responsibility at Pfizer,
most notably as Chief Counsel for Pfizer's Innovative Health global
business. Earlier in his career, he served as Chief Counsel for the
Vaccines, Oncology and Consumer Health global businesses at Pfizer,
as well as Assistant General Counsel for its Asia operations.
“I am honored and excited to join BeiGene at this stage of
growth,” said Chan Lee, incoming General Counsel, BeiGene. “I have
admired BeiGene’s vision to improve patients’ lives around the
world and look forward to partnering with my BeiGene colleagues
across functions and regions to further advance this
commitment.”
Mr. Lee will serve on BeiGene’s Executive Committee and report
directly to John V. Oyler.
About BeiGene
BeiGene is a global, science-driven biotechnology company
focused on developing innovative and affordable medicines to
improve treatment outcomes and access for patients worldwide. With
a broad portfolio of more than 40 clinical candidates, we are
expediting development of our diverse pipeline of novel
therapeutics through our own capabilities and collaborations. We
are committed to radically improving access to medicines for two
billion more people by 2030. BeiGene has a growing global team of
over 8,000 colleagues across five continents. To learn more about
BeiGene, please visit www.beigene.com and follow us on Twitter at
@BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
Chan Lee’s appointment and responsibilities as General Counsel and
BeiGene’s plans, commitments, aspirations and goals under the
heading “About BeiGene.” Actual results may differ materially from
those indicated in the forward-looking statements as a result of
various important factors, including BeiGene's ability to
demonstrate the efficacy and safety of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or marketing approval; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials and marketing approval; BeiGene's ability to
achieve commercial success for its marketed medicines and drug
candidates, if approved; BeiGene's ability to obtain and maintain
protection of intellectual property for its medicines and
technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing and other services; BeiGene’s limited
experience in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and the impact
of the COVID-19 pandemic on BeiGene’s clinical development,
regulatory, commercial, manufacturing, and other operations, as
well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220713005323/en/
Investor Contact Kevin Mannix +1 240-410-0129
ir@beigene.com
Media Contact Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024